Delivery Order SPE2D020D0005-SPE2D325F286A
Award Date 8/4/25
Potential Completion Date 8/7/25
Potential Value $1.1K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Congers, NY 10920, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to Chartwell RX LLC on September 2, 2025, for the supply of Ondansetron Orally Disintegrating Tablets (ODT) 4 mg in quantities of 30 tablets, with a ceiling value of $1,184.50. This is a firm fixed-price delivery order with an ultimate completion date of September 5, 2025, and carries no set-aside designation. The order will be fulfilled at Chartwell RX's facility located in Congers, New York. Chartwell RX LLC is an...
- The U.S. Department of Defense, through its Medical Supply Chain organization, awarded a delivery order to Chartwell RX LLC on July 14, 2025, for the supply of Ondansetron ODT (orally disintegrating tablets) 4 mg in quantities of 30 tablets. This firm fixed-price delivery order, valued at $1,184.50 with an ultimate completion date of July 17, 2025, represents a continuation of the Defense Logistics Agency's pharmaceutical supply chain operations. The award was not designated as a set-aside...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to Chartwell RX LLC on August 20, 2025, for the supply of Ondansetron ODT (orally disintegrating tablets) 4 mg in quantities of 30 tablets. This firm fixed-price delivery order, valued at $1,184.50, represents a continuation of pharmaceutical supply support to federal military and veteran healthcare services. The contract carries no set-aside designation and is set for completion by August 25, 2025, with fulfillment...
- The U.S. Department of Defense's Medical Supply Chain awarded a firm fixed-price delivery order to Chartwell RX LLC on September 5, 2025, for the supply of Ondansetron Orally Disintegrating Tablets (ODT) 4 mg in quantities of 30 tablets. The contract carries a ceiling value of $1,184.50 and is scheduled for completion by September 10, 2025. This delivery order is issued without a set-aside designation and represents a continuation of the government's ongoing pharmaceutical supply chain through...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $1,184.50 to Chartwell RX LLC on September 17, 2025, for the supply of Ondansetron Orally Disintegrating Tablets (ODT) 4 milligram in a 30-tablet quantity. This contract, which is not set aside for any specific business type, operates under a firm fixed-price arrangement with an ultimate completion date of September 22, 2025. Chartwell RX LLC, a for-profit pharmaceutical manufacturer and distributor based in...
- The U.S. Department of Defense Medical Supply Chain has awarded a delivery order valued at $1,578.48 to Chartwell RX LLC for the supply of Ondansetron ODT (orally disintegrating tablets) 8 mg in a quantity of 30 tablets. The contract was awarded on August 11, 2025, with an ultimate completion date of August 14, 2025, and carries a firm fixed price with no small business set-aside designation. Performance will be executed at Chartwell RX's facility located in Congers, New York. Chartwell RX...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to Chartwell RX LLC on September 2, 2025, for the supply of Ondansetron ODT (orally disintegrating tablets) 4 mg in quantities of 30 tablets. This is a firm fixed-price delivery order with a ceiling value of $3,553.50 and an ultimate completion date of September 5, 2025. The contract was awarded without a set-aside designation and will be performed at Chartwell RX's facility in Congers, New York. Ondansetron is...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $1,184.50 to Chartwell RX LLC for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. The award was issued on July 30, 2025, with an ultimate completion date of August 4, 2025, under a firm fixed-price contract type with no set-aside designation. Chartwell RX LLC, a pharmaceutical company headquartered in Congers, New York, will fulfill this order from its place of performance at the same...
- The U.S. Defense Department's Medical Supply Chain awarded a $1,776.75 firm fixed-price delivery order to Chartwell RX LLC on August 20, 2025, for the supply of Ondansetron Orally Disintegrating Tablets (ODT) 4 mg in a quantity of 30 tablets. The contract, issued without a set-aside designation, is scheduled for completion by August 25, 2025, with performance taking place at Chartwell RX's facility in Congers, New York. Ondansetron is an antiemetic medication commonly used to prevent nausea...
- The U.S. Defense Department's Medical Supply Chain awarded a $1,184.50 firm fixed-price delivery order to Chartwell RX LLC on September 3, 2025, for the supply of Ondansetron ODT (orally disintegrating tablets) 4 mg in a quantity of 30 tablets. The delivery order, which carries an ultimate completion date of September 8, 2025, was issued without a set-aside designation. Chartwell RX LLC, a pharmaceutical manufacturer and distributor headquartered in Congers, New York, has been registered in...